Breaking News, Promotions & Moves

Oxford Biomedica Names New Chief Financial Officer

Lucinda Crabtree Ph.D. succeeds Stuart Paynter, effective September 2, 2024.

Author Image

By: Charlie Sternberg

Associate Editor

Oxford Biomedica plc, a cell and gene therapy CDMO, has appointed Lucinda (Lucy) Crabtree Ph.D. as Chief Financial Officer (CFO) and Board member. Stuart Paynter will step down as CFO and from the Board after almost seven years of service. These changes will become effective on September 2, 2024 and Paynter will then transition away from Oxford Biomedica following a suitable handover period. About Lucinda Crabtree Crabtree was previously CFO at MorphoSys AG. As CFO of MorphoSys, she ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters